Compare Becton Dickinson and Co (BDX) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nutanix Inc — how do they compare? Becton Dickinson and Co trades at $182.09 (market cap $49.41B), while Nutanix Inc trades at $64.36 (market cap $17.39B). The key difference: Becton Dickinson and Co is far larger — about 2.8× Nutanix Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| BDX | NTNX | |
|---|---|---|
Market Cap | $49.41B | $17.39B |
Sector | Health | Technology |
52-Week High | $185.39 | $81.12 |
52-Week Low | $138.62 | $34.41 |
Enterprise Value | $65.51B | $16.90B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
Nutanix (NTNX) trades at $64.32, down 0.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.47 surpassing the $0.36 expectation. Revenue grew to $2.54B in 2025 with a net income margin of 7.42%, while 2026 projections show improved profitability. Analyst sentiment remains positive with 20 buy ratings and a $57.80 consensus price target.
The outlook for NTNX is supported by strong earnings momentum and institutional interest, though high valuation multiples (P/E 67.71) and supply chain risks noted in recent news pose challenges. The stock's proximity to resistance at $65.00 suggests near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
